Vauquelin Georges
a Free University Brussels (VUB), Molecular and Biochemical Pharmacology Department , Pleinlaan 2, B-1050 Brussels, Belgium +32 2 6291955 ; +32 2 6291358 ;
Expert Opin Drug Discov. 2015 Oct;10(10):1085-98. doi: 10.1517/17460441.2015.1067196. Epub 2015 Jul 13.
Optimal drug therapy often requires continuing high levels of target occupancy. Besides the traditional pharmacokinetic (PK) contribution thereto, drug-target interactions that comprise successive 'microscopic' steps as well as the intervention of the cell membrane and other 'micro'-anatomical structures nearby may help attaining this objective.
This article reviews the 'micro'-pharmacodynamic (PD) and PK mechanisms that may increase a drug's residence time. Special focus is on induced-fit- and bivalent ligand binding models as well as on the ability of the plasma membrane surrounding the target to act as a repository for the drug (e.g., microkinetic model), to actively participate in the binding process (e.g., exosite model) and, along with microanatomical elements like synapses and interstitial spaces, to act on the drug's diffusion properties (reduction in dimensionality and drug-rebinding models).
The PK profile, as well as the target dissociation kinetics of a drug, may fail to account for its long-lasting efficiency in intact tissues and in vivo. This lacuna could potentially be alleviated by incorporating some of the enumerated 'microscopic' mechanisms and, to unveil them, dedicated experiments on sufficiently physiologically relevant biological material like cell monolayers can already be implemented early on in the lead optimization process.
最佳药物治疗通常需要持续保持较高的靶点占有率。除了传统的药代动力学(PK)对此的贡献外,药物 - 靶点相互作用包含连续的“微观”步骤,以及细胞膜和附近其他“微观”解剖结构的干预,可能有助于实现这一目标。
本文综述了可能增加药物驻留时间的“微观”药效学(PD)和PK机制。特别关注诱导契合和二价配体结合模型,以及围绕靶点的质膜作为药物储存库的能力(例如微观动力学模型)、积极参与结合过程的能力(例如别构位点模型),以及与突触和间隙等微观解剖学元素一起作用于药物扩散特性的能力(维度降低和药物再结合模型)。
药物的PK概况以及靶点解离动力学可能无法解释其在完整组织和体内的持久疗效。通过纳入一些列举的“微观”机制,有可能弥补这一空白,并且为了揭示这些机制,在先导优化过程的早期就可以对足够生理相关的生物材料(如细胞单层)进行专门实验。